---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-127783"
form_type: "8-K"
ticker: "ANAB"
cik: "0001370053"
company_name: "ANAPTYSBIO, INC"
filed_at: "2026-03-27T23:59:59+00:00"
generated_at: "2026-05-15T08:34:38.432459+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# AnaptysBio approves spin-off of First Tracks Biotherapeutics; distribution set for April 20, 2026

## Summary
- Anaptys stockholders to receive one share of First Tracks Bio (TRAX) per ANAB share held on April 6, 2026; distribution expected pre-market April 20, 2026.
- First Tracks Bio launches with $180M cash ($100M from Anaptys + $80M from private placement at $13.81/share) and a two-year cash runway.
- Post-spin Anaptys to manage Jemperli (GSK) and imsidolimab (Vanda) royalties; virtual model with <10 FTEs and <$10M annual opex; $100M stock repurchase plan authorized.
- Susannah Gray (former Royalty Pharma CFO) appointed to Anaptys board; Dennis Mulroy and Eric Loumeau to exit with separation agreements.
- Anaptys terminates existing ATM sales agreement with TD Securities.

## SEC filing metadata
- accession: 0001193125-26-127783
- form_type: 8-K
- ticker: ANAB
- cik: 0001370053
- company_name: ANAPTYSBIO, INC
- filed_at: 2026-03-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 1.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1370053/000119312526127783/0001193125-26-127783-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1370053/000119312526127783/d122216d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-127783
- JSON: https://secwatch.observer/filing/0001193125-26-127783.json
- Plain text: https://secwatch.observer/filing/0001193125-26-127783.txt

## Key facts
- Material Agreements
  ANAPTYSBIO, INC entered into Purchase Agreement with certain third party investors valued at approximately $80 million (effective 2026-03-26).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain third party investors
  - Value: approximately $80 million
  - Effective: 2026-03-26
  source text: On March 26, 2026, First Tracks Biotherapeutics and EcoR1 Capital Fund Qualified, L.P. (the “Selling Stockholder”) entered into a purchase agreement (the “Purchase Agreement”) with certain third party investors (collectively, the “Investors”), pursuant to which SpinCo agreed to issue and sell an aggregate 5,791,478 shares of SpinCo’s common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1370053/000119312526127783/0001193125-26-127783-index.htm
- Material Agreements
  ANAPTYSBIO, INC terminated Sales Agreement with TD Securities (USA) LLC (effective 2024-11-05).
  - Action: termination
  - Agreement: atm program
  - Counterparty: TD Securities (USA) LLC
  - Effective: 2024-11-05
  source text: As previously disclosed, on November 5, 2024, the Company entered into a Sales Agreement (the “Sales Agreement”) with TD Securities (USA) LLC (the “Agent”), pursuant to which the Company could issue and sell, from time to time, shares of its common stock, par value $0.001 per share (the “Common Shares”), up to an aggregate offering price equal to the Maximum Amount (the “ATM Program”). The Company has issued a termination letter to the Agent to terminate the Sales Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1370053/000119312526127783/0001193125-26-127783-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.